EP2184984A4 - N- (ARYLAMINO) ARYLSULFONAMIDE DERIVATIVES COMPRISING POLYMORPHS AS MEK INHIBITORS AND COMPOSITIONS, METHODS OF USE AND PREPARATION METHODS THEREOF - Google Patents

N- (ARYLAMINO) ARYLSULFONAMIDE DERIVATIVES COMPRISING POLYMORPHS AS MEK INHIBITORS AND COMPOSITIONS, METHODS OF USE AND PREPARATION METHODS THEREOF

Info

Publication number
EP2184984A4
EP2184984A4 EP08796733.7A EP08796733A EP2184984A4 EP 2184984 A4 EP2184984 A4 EP 2184984A4 EP 08796733 A EP08796733 A EP 08796733A EP 2184984 A4 EP2184984 A4 EP 2184984A4
Authority
EP
European Patent Office
Prior art keywords
methods
arylamino
mek
inhibitors
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP08796733.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2184984A1 (en
Inventor
Jean-Michel Vernier
Colin Edward Rowlings
Jean-Luc Girardet
Stuart Dimock
Barry Quart
Jeffrey N Miner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardea Biociences Inc
Original Assignee
Ardea Biociences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2184984(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Application filed by Ardea Biociences Inc filed Critical Ardea Biociences Inc
Publication of EP2184984A1 publication Critical patent/EP2184984A1/en
Publication of EP2184984A4 publication Critical patent/EP2184984A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
    • A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
    • A01N41/04—Sulfonic acids; Derivatives thereof
    • A01N41/06—Sulfonic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
EP08796733.7A 2007-07-30 2008-07-28 N- (ARYLAMINO) ARYLSULFONAMIDE DERIVATIVES COMPRISING POLYMORPHS AS MEK INHIBITORS AND COMPOSITIONS, METHODS OF USE AND PREPARATION METHODS THEREOF Ceased EP2184984A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446408P 2008-03-06 2008-03-06
US3446608P 2008-03-06 2008-03-06
US4488608P 2008-04-14 2008-04-14
PCT/US2008/071392 WO2009018233A1 (en) 2007-07-30 2008-07-28 Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Publications (2)

Publication Number Publication Date
EP2184984A1 EP2184984A1 (en) 2010-05-19
EP2184984A4 true EP2184984A4 (en) 2013-07-24

Family

ID=40304796

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08796733.7A Ceased EP2184984A4 (en) 2007-07-30 2008-07-28 N- (ARYLAMINO) ARYLSULFONAMIDE DERIVATIVES COMPRISING POLYMORPHS AS MEK INHIBITORS AND COMPOSITIONS, METHODS OF USE AND PREPARATION METHODS THEREOF

Country Status (23)

Country Link
EP (1) EP2184984A4 (zh)
JP (3) JP2010535232A (zh)
KR (3) KR20150091434A (zh)
CN (2) CN103479604B (zh)
AP (1) AP2817A (zh)
AU (2) AU2008282338B2 (zh)
BR (1) BRPI0815659A2 (zh)
CA (1) CA2693390C (zh)
CO (1) CO6470808A2 (zh)
CR (1) CR11244A (zh)
DO (1) DOP2010000045A (zh)
EA (2) EA032294B1 (zh)
EC (1) ECSP109910A (zh)
HK (1) HK1147396A1 (zh)
HN (1) HN2010000203A (zh)
IL (1) IL203296A (zh)
MA (1) MA31881B1 (zh)
MX (1) MX2010001244A (zh)
NZ (1) NZ582929A (zh)
PH (1) PH12015501914A1 (zh)
SV (1) SV2010003469A (zh)
TN (1) TN2010000049A1 (zh)
WO (1) WO2009018233A1 (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US8808742B2 (en) * 2008-04-14 2014-08-19 Ardea Biosciences, Inc. Compositions and methods for preparing and using same
KR102560207B1 (ko) * 2008-09-09 2023-07-27 에프. 호프만-라 로슈 아게 아실 설폰아미드의 다형체
AU2009296246B2 (en) 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US8673876B2 (en) * 2009-03-11 2014-03-18 Ardea Biosciences Inc. Pharmaceutical combinations for treatment of specific cancers
UY32486A (es) * 2009-03-11 2010-10-29 Ardea Biosciences Inc Tratamiento del cáncer de páncreas
US9034861B2 (en) 2009-10-13 2015-05-19 Allomek Therapeutics Llc MEK inhibitors useful in the treatment of diseases
EP2491015A1 (en) * 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
CN102649773A (zh) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途
KR102027448B1 (ko) * 2011-04-28 2019-10-01 슬로안-케테링인스티튜트퍼캔서리서치 Hsp90 병용요법
MY186875A (en) * 2011-05-27 2021-08-26 Bayer Ip Gmbh Chiral synthesis of n-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamides
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
CN104394855A (zh) * 2012-05-31 2015-03-04 拜耳医药股份有限公司 用于测定肝细胞癌(hcc)患者的治疗的有效响应的生物标记
MY194911A (en) 2012-06-04 2022-12-22 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
PT3702351T (pt) * 2012-10-19 2024-01-17 Array Biopharma Inc Formulação contendo um inibidor de mek
EP2916859B1 (en) 2012-11-02 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
EP2848246A1 (en) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
JP6910946B2 (ja) * 2014-08-25 2021-07-28 アイミューン セラピューティクス，インコーポレイテッド タマゴのタンパク質製剤およびその製造方法
WO2016141068A1 (en) 2015-03-03 2016-09-09 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibtor
JP7045726B2 (ja) * 2017-06-16 2022-04-01 ベータ ファーマ，インコーポレイテッド Ｎ－（２－（２－（ジメチルアミノ）エトキシ）－４－メトキシ－５－（（４－（１－メチル－１ｈ－インドール－３－イル）ピリミジン－２－イル）アミノ）フェニル）アクリルアミドおよびその塩の医薬品製剤
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014011A2 (en) * 2005-07-21 2007-02-01 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (ja) * 1992-07-31 1997-01-29 塩野義製薬株式会社 トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
KR100336699B1 (ko) * 1992-08-25 2002-05-13 윌리암스 로저 에이 레트로바이러스 프로테아제 저해제로서 유용한히드록시에틸아미노 술폰아미드
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
IL144215A0 (en) * 1999-01-13 2002-05-23 Warner Lambert Co 1-heterocycle substituted diarylamines
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
CN100441176C (zh) * 2001-09-24 2008-12-10 杰西·L·S·奥 测定联合疗法中使用的苏拉明的化学敏感化剂量的方法和组合物
JP2006502117A (ja) * 2002-07-17 2006-01-19 タイタン ファーマシューティカルズ インコーポレイテッド 抗腫瘍活性を上昇させるための化学療法薬物の組み合わせ
CA2493023C (en) * 2002-07-30 2012-01-31 Zentaris Gmbh Use of alkylphosphocholines in combination with antitumor medicaments
BRPI0607537A2 (pt) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd formulações de derivado de quinazolina nanoparticulado
PE20061317A1 (es) * 2005-04-22 2006-12-29 Kissei Pharmaceutical Cristal polimorfico de hidrocloruro del acido 4'-{2-[(1s,2r)-2-hidroxi-2-(4-hidroxifenil)-1-metiletilamino]etoxi}-3-isopropil-3'-5'-dimetilbifenilcarboxilico
JP2007099763A (ja) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd ピペラシリンナトリウム・１水和物の新規な結晶及びその製造方法
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014011A2 (en) * 2005-07-21 2007-02-01 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022, ISBN: 978-3-540-36760-4, DOI: 10.1007/3-540-69178-2_5 *
See also references of WO2009018233A1 *

Also Published As

Publication number Publication date
HK1147396A1 (en) 2011-08-12
CA2693390A1 (en) 2009-02-05
ECSP109910A (es) 2010-04-30
KR20100092424A (ko) 2010-08-20
CN103479604A (zh) 2014-01-01
AP2010005134A0 (en) 2010-02-28
TN2010000049A1 (en) 2011-09-26
KR20140098185A (ko) 2014-08-07
CA2693390C (en) 2017-01-17
JP2017125021A (ja) 2017-07-20
BRPI0815659A2 (pt) 2014-09-30
EA032294B1 (ru) 2019-05-31
CN101808516B (zh) 2013-08-28
CR11244A (es) 2010-05-20
PH12015501914A1 (en) 2017-07-31
DOP2010000045A (es) 2010-10-31
HN2010000203A (es) 2012-11-19
NZ582929A (en) 2012-03-30
CO6470808A2 (es) 2012-06-29
CN101808516A (zh) 2010-08-18
IL203296A (en) 2017-06-29
KR20150091434A (ko) 2015-08-10
AP2817A (en) 2013-12-31
WO2009018233A1 (en) 2009-02-05
EA020624B1 (ru) 2014-12-30
EA201400552A1 (ru) 2014-09-30
JP2015078199A (ja) 2015-04-23
EA201000268A1 (ru) 2010-08-30
JP6309880B2 (ja) 2018-04-11
EP2184984A1 (en) 2010-05-19
MA31881B1 (fr) 2010-12-01
MX2010001244A (es) 2010-08-31
CN103479604B (zh) 2016-08-10
AU2008282338B2 (en) 2015-02-12
SV2010003469A (es) 2010-04-30
JP2010535232A (ja) 2010-11-18
AU2015200390B2 (en) 2017-02-23
AU2008282338A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
HK1147396A1 (en) Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
AU2015200390A1 (en) Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
IL222698A0 (en) Benzazole derivatives, compositions, and methods of use as b- secretase inhibitors
IL192580A0 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
ZA201209297B (en) 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
WO2011032169A3 (en) Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
IL204437A (en) History of aryl cyclic profile and their use
HK1164876A1 (en) 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
DK3461503T3 (da) Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder
IL218669A (en) Compounds Effective as Xanthine Oxidase Inhibitors, a Method for their Preparation and Pharmaceuticals Containing Them
ZA200905671B (en) Heterocyclic compounds, compositions comprising them and methods of their use
UA99485C2 (ru) Хиназолиндионовые производные, их получение и их применение в терапии
HRP20130585T1 (en) Alkylthiazol carbamate derivatives, preparation thereof and their use as faah inhibitors
EP1954685A4 (en) FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
ZA200908612B (en) 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
WO2009007535A3 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
IL206153A0 (en) Rna antagonist compounds for the modulation of pik3ca compositions comprising the same and uses thereof
IL179076A0 (en) Azasugasr derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof
EP2320738A4 (en) SUBSTITUTED AMINOTHIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF
IL200795A0 (en) Prodrug compounds of (+)3-hydroxymorphinan, compositions comprising the same and use thereof
TH0901000961A (th) อนุพันธ์ของ n-(แอริลอะมิโน) ซัลโฟนาไมด์ ที่รวมถึงพหุสัณฐานในฐานะตัวยับยั้งของ mek และสารองค์ประกอบ, วิธีการของการใช้ และวิธีการสำหรับการเตรียมสารชนิดเดียวกันนั้น
EP2213650A4 (en) SUBSTITUTED DIPHENYLAMINES AS INHIBITORS OF THE REVERSE TRANSCRIPTASE, PROCESS FOR THEIR PREPARATION AND THE APPLICATION THEREOF
TH148538B (th) อนุพันธ์ของ n-(แอริลอะมิโน) ซัลโฟนาไมด์ ที่รวมถึงพหุสัณฐานในฐานะตัวยับยั้งของ mek และสารองค์ประกอบ,วิธีการของการใช้ และวิธีการสำหรับการเตรียมสารชนิดเดียวกันนั้น
WO2010077734A3 (en) Novel antiviral compounds, compositions, and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100301

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RAX Requested extension states of the european patent have changed

Extension state: MK

Payment date: 20100503

Extension state: BA

Payment date: 20100503

Extension state: AL

Payment date: 20100503

Extension state: RS

Payment date: 20100503

A4 Supplementary search report drawn up and despatched

Effective date: 20130621

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/18 20060101ALI20130617BHEP

Ipc: A01N 41/06 20060101AFI20130617BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ARDEA BIOSCIENCES, INC.

17Q First examination report despatched

Effective date: 20150626

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20180425